Right now, doctors prescribe drugs mostly by trial and error — if the first one doesn't work or causes side effects, they try another. But your DNA actually holds clues about which drugs will work best for you and which ones could be harmful. U-PGx tested a system where patients get a simple genetic test upfront, and the results are stored in their medical record so that every doctor who prescribes a drug can check it first. They rolled this out across 7 hospitals in different European countries to see if it actually works in the real world.
Adverse drug reactions cost healthcare systems billions annually, and a significant portion could be prevented if doctors knew in advance how a patient's genetics would affect their response to specific medications. Most hospitals today lack the IT infrastructure and clinical decision support tools to make genetic data actionable at the point of prescribing. The result is continued trial-and-error prescribing, patient harm, and wasted healthcare spending.
The project built and validated a complete system for pre-emptive pharmacogenomic testing: open-source software with a semantic model for embedding genetic results into electronic health records, validated specifications for pharmacogenomic assays, clinical guidelines for drug-gene interactions, and ELSI (ethical/legal) resources. All components were tested across 7 real hospital environments in 10 countries, producing 58 deliverables in total.
If you are a health IT vendor struggling to integrate genetic data into clinical workflows — this project developed open-source software and a semantic model that embeds pharmacogenomic results directly into electronic health records. It was tested across 7 different European healthcare environments, proving interoperability across diverse hospital systems.
If you are a diagnostic company looking to expand your pharmacogenomic assay portfolio — this project produced a validated set of specifications for PGx assays covering the most clinically important drug-gene interactions. These specifications were developed with input from 22 consortium partners across 10 countries, ensuring broad clinical relevance.
If you are a health insurer dealing with rising costs from adverse drug reactions and ineffective prescriptions — this project generated real-world cost-effectiveness data from 7 European healthcare settings. The evidence base can support reimbursement decisions for pre-emptive pharmacogenomic testing programs.
The project investigated cost-effectiveness across 7 European healthcare environments, but specific per-patient or per-hospital cost figures are not available in the public dataset. The open-source software components would reduce IT integration costs. Contact the consortium for detailed health-economic data from their implementation studies.
The project was specifically designed for large-scale implementation, testing across 7 different European healthcare environments in 10 countries. This diversity — covering different health system organizations and settings — was intentional to prove scalability and adaptability across varied clinical contexts.
The project released open-source software artefacts describing the semantic model, which suggests free availability for integration. The pharmacogenomics guidelines build on existing clinical guidelines. Specific licensing terms should be confirmed with the coordinator at Leiden University Medical Center.
The project included dedicated work on Ethical, Legal and Social Implications (ELSI), producing educational content and addressing regulatory considerations. Given the sensitive nature of genetic data, GDPR compliance was a core design requirement across all 7 implementation sites.
Based on available project data, the consortium ran implementations over a multi-year period (2016-2021) across 7 sites. The timeline for a single hospital would depend on existing IT infrastructure and electronic health record systems. The open-source semantic model and assay specifications should accelerate deployment.
The project was built around embedding pharmacogenomic data into existing electronic health records. The open-source semantic model software was specifically designed for interoperability. Testing across 7 different European healthcare environments with diverse IT systems demonstrates adaptability to different EHR platforms.
The project closed in December 2021 after producing 58 deliverables including software, specifications, and clinical guidelines. The coordinator at Leiden University Medical Center (Netherlands) and the network of 22 partners across 10 countries remain potential sources of expertise and collaboration.
The U-PGx consortium brings together 22 partners from 10 European countries, anchored by Leiden University Medical Center in the Netherlands — one of Europe's leading pharmacogenomics research hospitals. The mix includes 10 universities and 7 research organizations providing deep scientific expertise, plus 3 industry partners (including 2 SMEs) ensuring commercial relevance. The 14% industry ratio is typical for a research-intensive health project, but the real strength is geographic coverage: implementations spanning Austria, Germany, Greece, Spain, France, Italy, Netherlands, Sweden, Slovenia, and the UK give the results credibility across diverse healthcare systems. For a business considering adoption, this means the approach has already been stress-tested against different regulatory environments, IT infrastructures, and clinical workflows.
Leiden University Medical Center (Academisch Ziekenhuis Leiden), Netherlands — reach out to the pharmacogenomics or personalized medicine department
Want to explore how pharmacogenomic testing could reduce adverse drug reactions in your hospital network or product portfolio? SciTransfer can connect you with the U-PGx team and help evaluate fit for your specific clinical or commercial context.
